Search Results - "Dragnev, Konstantin"

Biomarker-Driven Personalized Immunoprevention: Toward More Efficient Clinical Trials? by Yendamuri, Sai, Dragnev, Konstantin H

“…In this secondary analysis of specimens from the CANTOS trial, the investigators find that patients with clonal hematopoiesis mutations, particularly in the…”
Get more information

Early Versus Delayed Initiation of Concurrent Palliative Oncology Care: Patient Outcomes in the ENABLE III Randomized Controlled Trial by Bakitas, Marie A, Tosteson, Tor D, Li, Zhigang, Lyons, Kathleen D, Hull, Jay G, Li, Zhongze, Dionne-Odom, J Nicholas, Frost, Jennifer, Dragnev, Konstantin H, Hegel, Mark T, Azuero, Andres, Ahles, Tim A

“…Randomized controlled trials have supported integrated oncology and palliative care (PC); however, optimal timing has not been evaluated. We investigated the…”
Get full text

Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A by Reckamp, Karen L, Redman, Mary W, Dragnev, Konstantin H, Minichiello, Katherine, Villaruz, Liza C, Faller, Bryan, Al Baghdadi, Tareq, Hines, Susan, Everhart, Leah, Highleyman, Louise, Papadimitrakopoulou, Vassiliki, Neal, Joel W, Waqar, Saiama N, Patel, Jyoti D, Gray, Jhanelle E, Gandara, David R, Kelly, Karen, Herbst, Roy S

“…Resistance to immune checkpoint inhibition (ICI) in advanced non-small-cell lung cancer (NSCLC) represents a major unmet need. Combining ICI with vascular…”
Get full text

Benefits of Early Versus Delayed Palliative Care to Informal Family Caregivers of Patients With Advanced Cancer: Outcomes From the ENABLE III Randomized Controlled Trial by Dionne-Odom, J Nicholas, Azuero, Andres, Lyons, Kathleen D, Hull, Jay G, Tosteson, Tor, Li, Zhigang, Li, Zhongze, Frost, Jennifer, Dragnev, Konstantin H, Akyar, Imatullah, Hegel, Mark T, Bakitas, Marie A

“…To determine the effect of early versus delayed initiation of a palliative care intervention for family caregivers (CGs) of patients with advanced cancer…”
Get full text

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: Focus on epidermal growth factor receptor mutation testing and mutation-positive patients by Roengvoraphoj, Monic, Tsongalis, Gregory J, Dragnev, Konstantin H, Rigas, James R

“…Abstract Activation of the epidermal growth factor receptor (EGFR) pathway has been implicated in tumorigenesis in non-small cell lung cancer (NSCLC), the most…”
Get full text

A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer by Bayliss, Trevor J, Smith, Jeff T, Schuster, Michael, Dragnev, Konstantin H, Rigas, James R

“…Inflammatory pathways may be an important contributor to morbidity and mortality associated with lung cancer. The oncogene-associated inflammatory…”
Get more information

Role of Neoadjuvant Immune Checkpoint Inhibitors in Resectable Non-Small Cell Lung Cancer by Riano, Ivy, Abuali, Inas, Sharma, Aditya, Durant, Jewelia, Dragnev, Konstantin H

“…The neoadjuvant use of immune checkpoint inhibitors (ICI) in resectable non-small cell lung cancer (NSCLC) is being increasingly adopted, but questions about…”
Get full text

Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies by Weiss, Jared, Goldschmidt, Jerome, Andric, Zoran, Dragnev, Konstantin H., Gwaltney, Chad, Skaltsa, Konstantina, Pritchett, Yili, Antal, Joyce M., Morris, Shannon R., Daniel, Davey

“…[Display omitted] Chemotherapy-induced myelosuppression (CIM) and its sequalae cause significant side effects and harm to quality of life. Trilaciclib is an…”
Get full text

MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors by Liu, Xi, Sempere, Lorenzo F, Ouyang, Haoxu, Memoli, Vincent A, Andrew, Angeline S, Luo, Yue, Demidenko, Eugene, Korc, Murray, Shi, Wei, Preis, Meir, Dragnev, Konstantin H, Li, Hua, Direnzo, James, Bak, Mads, Freemantle, Sarah J, Kauppinen, Sakari, Dmitrovsky, Ethan

“…MicroRNAs (miRNAs) regulate gene expression. It has been suggested that obtaining miRNA expression profiles can improve classification, diagnostic, and…”
Get full text

The beginning of the perioperative immunotherapy era in early-stage non-small cell lung cancer by Riano, Ivy, Dragnev, Konstantin H., Phillips, Joseph D.

Get full text

PRIMARY PREVENTION AND INTERCEPTION STUDIES IN RAS-MUTATED TUMOR MODELS EMPLOYING SMALL MOLECULES OR VACCINES by Dragnev, Konstantin H, Lubet, Ronald A, Miller, Mark Steven, Sei, Shizuko, Fox, Jennifer T, You, Ming

“…Therapeutic targeting of RAS-mutated cancers is difficult, whereas prevention or interception (treatment before or in the presence of preinvasive lesions)…”
Get full text

Clinical outcomes in non-small-cell lung cancer patients receiving concurrent metformin and immune checkpoint inhibitors by Afzal, Muhammad Z, Dragnev, Konstantin, Sarwar, Tayyaba, Shirai, Keisuke

“…To study the clinical benefits of concurrent metformin and immune checkpoint inhibitors (ICIs) in non-small-cell lung cancer patients. This is a retrospective…”
Get full text

Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss by Bouley, Stephanie J, Grassetti, Andrew V, Allaway, Robert J, Wood, Matthew D, Hou, Helen W, Burdon Dasbach, India R, Seibel, William, Wu, Jimmy, Gerber, Scott A, Dragnev, Konstantin H, Walker, James A, Sanchez, Yolanda

“…Neurofibromatosis type 1, a genetic disorder caused by pathogenic germline variations in NF1, predisposes individuals to the development of tumors, including…”
Get full text

Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non-Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042) by Gadgeel, Shirish M, Miao, Jieling, Riess, Jonathan W, Moon, James, Mack, Philip C, Gerstner, Gregory J, Burns, Timothy F, Taj, Asma, Akerley, Wallace L, Dragnev, Konstantin H, Laudi, Noel, Redman, Mary W, Gray, Jhanelle E, Gandara, David R, Kelly, Karen

“…Efficacy of MEK inhibitors in KRAS+ NSCLC may differ based on specific KRAS mutations and comutations. Our hypothesis was that docetaxel and trametinib would…”
Get full text

CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy by Lai, Anne Y, Sorrentino, Jessica A, Dragnev, Konstantin H, Weiss, Jared M, Owonikoko, Taofeek K, Rytlewski, Julie A, Hood, Jill, Yang, Zhao, Malik, Rajesh K, Strum, Jay C, Roberts, Patrick J

“…Combination treatment with chemotherapy and immune checkpoint inhibitors (ICIs) has demonstrated meaningful clinical benefit to patients. However,…”
Get full text

Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth‐Hitchcock Medical Center by Tafe, Laura J., Gorlov, Ivan P., Abreu, Francine B., Lefferts, Joel A., Liu, Xiaoying, Pettus, Jason R., Marotti, Jonathan D., Bloch, Kasia J., Memoli, Vincent A., Suriawinata, Arief A., Dragnev, Konstantin H., Fadul, Camilo E., Schwartz, Gary N., Morgan, Clinton R., Holderness, Britt M., Peterson, Jason D., Tsongalis, Gregory J., Miller, Todd W., Chamberlin, Mary D.

“…Background. Although genetic profiling of tumors is a potentially powerful tool to predict drug sensitivity and resistance, its routine use has been limited…”
Get full text

The Role of a Palliative Care Intervention in Moderating the Relationship Between Depression and Survival Among Individuals With Advanced Cancer by Prescott, Anna T, Hull, Jay G, Dionne-Odom, J. Nicholas, Tosteson, Tor D, Lyons, Kathleen Doyle, Li, Zhigang, Li, Zhongze, Dragnev, Konstantin H, Hegel, Mark T, Steinhauser, Karen E, Ahles, Tim A, Bakitas, Marie A

“…Objective: Randomized controlled trials (RCTs) of early palliative care interventions in advanced cancer have positively impacted patient survival, yet the…”
Get full text

A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER by Goldman, Jonathan W, Mazieres, Julien, Barlesi, Fabrice, Dragnev, Konstantin H, Koczywas, Marianna, Göskel, Tuncay, Cortot, Alexis B, Girard, Nicolas, Wesseler, Claas, Bischoff, Helge, Nadal, Ernest, Park, Keunchil, Lu, Shun, Taus, Alvaro, Cobo, Manuel, Estrem, Shawn T, Wijayawardana, Sameera R, Turner, Kellie, Oakley, 3rd, Gerard Joseph, Hurt, Karla C, Chiang, Alan Y, Hossain, Anwar M, John, William J, Paz-Ares, Luis

“…JUNIPER compared the efficacy and safety of abemaciclib, a selective cyclin-dependent kinase 4 and 6 inhibitor, with erlotinib in patients with non-small cell…”
Get full text

Uncovering Growth-Suppressive MicroRNAs in Lung Cancer by XI LIU, SEMPERE, Lorenzo F, DIRENZO, James, KORC, Murray, COLE, Charles N, BAK, Mads, KAUPPINEN, Sakari, DMITROVSKY, Ethan, GALIMBERTI, Fabrizio, FREEMANTLE, Sarah J, BLACK, Candice, DRAGNEV, Konstantin H, YAN MA, FIERING, Steven, MEMOLI, Vincent, HUA LI

“…Purpose: MicroRNA (miRNA) expression profiles improve classification, diagnosis, and prognostic information of malignancies, including lung cancer. This study…”
Get full text

A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer by Byers, Lauren Averett, Navarro, Alejandro, Schaefer, Eric, Johnson, Melissa, Özgüroğlu, Mustafa, Han, Ji-Youn, Bondarenko, Igor, Cicin, Irfan, Dragnev, Konstantin H., Abel, Adam, Wang, Xuejing, McNeely, Samuel, Hynes, Scott, Lin, Aimee Bence, Forster, Martin

“…This study assessed the checkpoint kinase 1 inhibitor prexasertib in patients with extensive-stage small-cell lung cancer (ED-SCLC). This was a parallel-cohort…”
Get full text